Located in Montreal, Inversago Pharma is a privately-owned Canadian biotech company at clinical-stage, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists. The Company aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Diabetic Kidney Disease (DKD), including Diabetic Nephropathy, Type 1 and Type 2 Diabetes (T1D / T2D), Non-Alcoholic Steatohepatitis (NASH), complications of obesity, hypertriglyceridemia (HTG), as well as fibrotic indications such as Progressive Fibrosis – Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis (IPF).
View Top Employees from Inversago PharmaWebsite | http://www.inversago.com |
Revenue | $405000 |
Funding | $42 million |
Employees | 22 (22 on RocketReach) |
Founded | 2015 |
Address | 1100 Boulevard René-Lévesque O, #1110, Montreal, Quebec H3B 4N4, CA |
Phone | (514) 922-2383 |
Industry | Pharmaceuticals, Biotechnology Research, Drug Manufacturing & Research, Biopharma, Drug Discovery, Biotechnology, Healthcare, Health Care, Science and Engineering, Medical, Pharmaceutical |
SIC | SIC Code 28 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 325 Companies, NAICS Code 541 Companies, NAICS Code 3254 Companies, NAICS Code 32541 Companies, NAICS Code 32 Companies, NAICS Code 54 Companies |
Looking for a particular Inversago Pharma employee's phone or email?
The Inversago Pharma annual revenue was $405000 in 2024.
François Ravenelle is the President and Chief Executive Officer of Inversago Pharma.
22 people are employed at Inversago Pharma.
Inversago Pharma is based in Montreal, Quebec.
The NAICS codes for Inversago Pharma are [325, 541, 3254, 32541, 32, 54].
The SIC codes for Inversago Pharma are [28, 283].